India’s Nicotine Policy Needs to Catch Up with Evidence

Nicotine Pouches · Image: Photo by Canndid UK / Unsplash
India’s radical response to nicotine pouches raises a question that goes beyond a single product: can a policy protect consumers if it barely distinguishes among different risk levels? As authorities tighten their grip on these products over youth access and addiction, the debate ignores an important distinction. Nicotine is addictive, and no nicotine product is risk-free. Yet nicotine and cigarette smoke are not the same. Smoke from cigarettes exposes consumers to thousands of chemicals produced by combustion, which is simply not the case for alternative non-smoking products. Even India’s recent tobacco harm reduction discussions have emphasized distinguishing nicotine from other harms of smoking and acknowledging that different products can carry different risk levels, which poses an opportunity to engage in harm reduction and help smokers switch to better alternatives (with the aim of helping them quit).
Findings from a study conducted by the Indian Council of Medical Research's National Institute of Cancer Prevention and Research highlight the growing presence of nicotine pouches in India. They were being sold in seven of the ten cities surveyed. Researchers identified 68 brands across online platforms and third party e-commerce sites, offering 445 flavours and labelled nicotine strengths ranging from 2Mg to 120Mg per pouch. The availability of different products and strengths is not, in itself, a problem. Consumers should have freedom to choose among valid alternatives, provided they have reliable information about the contents of the products and the risks involved. The concern is market growth without proper quality standards, leaving consumers no confidence over the products they purchased.
There is a bigger question for policymakers: how can India regulate these products to protect young consumers while providing adults better access to controlled, safer alternatives? The government instead has responded with harsher scrutiny. The Drugs Technical Advisory Board has recommended against approving new nicotine formulations, amid concerns about addiction and the risks associated with nicotine pouches. Enforcement alone cannot dictate how the market should be regulated. When products vary in nicotine strength, quality and composition, consumers need reliable information about their content and the risks associated with the product.
Regulators need clear standards to categorize compliant products and distinguish them from unregulated and unsafe ones. A framework that establishes requirements for product quality, nicotine content, packaging, marketing, and age restrictions would give authorities a strong basis for action. Without it, restrictions may curb sales without addressing product accountability.
The United States, for example, shows how regulators can distinguish between specific products. The Food and Drug Administration (FDA) in June 2026 authorized 20 ZYN nicotine pouch products after scientific review, which concluded that switching to these products from cigarettes significantly reduces exposure to various harmful chemicals associated with smoking. Sweden also regulates tobacco-free nicotine products through specific rules covering product notification, product requirements, sales and marketing.
A major takeaway for India is that regulation can account for differences between products without compromising public health safeguards. Evidence about one product cannot be applied to other pouches with varying nicotine strength. Nor should nicotine pouches be presented as proven smoking cessation tools without proper scientific proof. These limitations make product-specific assessment more important.
An effective regulatory framework should focus on clear product standards, transparent nicotine labelling and safeguards against marketing to minors. Retailers and online platforms should be held responsible for ensuring that products meet these requirements, while regulators should act firmly against illicit sales and misleading health claims. The aim should be to make the market more transparent and accountable, giving consumers better information while allowing regulation to reflect the differences between products rather than applying a blanket approach.
India’s tobacco policy should be ambitious enough to reduce smoking, but flexible enough to recognize that innovation can change the tools available to consumers. Regulation should manage the risks of new products without automatically shutting down the potential benefits they may offer. For India, the better path is not an unregulated nicotine market. It is a risk-proportionate regulatory framework that protects consumers while leaving room for evidence, competition and innovation to improve the alternatives available to adult smokers.
Shrey Madaan, Indian Policy Associate, Consumer Choice Center



